Sherry Korczynski's Promotion at Aquestive Therapeutics
Recently, Aquestive Therapeutics, Inc. (NASDAQ: AQST) made headlines with the promotion of Sherry Korczynski to Chief Commercial Officer from her previous role as Senior Vice President of Sales and Marketing. This change is particularly exciting as the company gears up for its pivotal product, Anaphylm, which aims to revolutionize the way epinephrine is delivered to patients.
The Vision for Anaphylm
Sherry Korczynski's impressive record in the allergy market makes her the perfect fit for her new position. Daniel Barber, President and CEO of Aquestive, expressed confidence in her ability to lead the company's global commercial strategy. Anaphylm has the potential to be groundbreaking as it offers a device-free, orally delivered option for epinephrine, designed to help those at risk of anaphylaxis.
A Career Marked by Accomplishments
Korczynski has built a solid reputation over her more than twenty years in the pharmaceutical industry. Her journey began with significant roles in various prominent firms such as ANI Pharmaceuticals, Eagle Pharmaceuticals, and Mylan, where she oversaw the marketing of the EpiPen. With her educational background, including a B.S. in Marketing from The Pennsylvania State University and an M.B.A. from West Virginia University, she brings a wealth of knowledge and experience to her role at Aquestive.
About Anaphylm: A Groundbreaking Product
Anaphylm, which is a sublingual film containing epinephrine, could redefine how individuals react to anaphylactic emergencies. The film's compact design allows it to be easily carried, weighing less than an ounce and being smaller than a credit card. Importantly, it doesn’t require water for administration, making it practical for emergency situations.
Aquestive Therapeutics: Innovating Patient Care
Aquestive Therapeutics continues to focus on improving patient lives through innovative delivery methods. By working on orally administered products, the company aims to offer alternatives that surpass traditional, more invasive treatments. Currently, they have four commercialized products already making an impact in the market, leveraging their unique technologies such as PharmFilm®.
Looking Forward
Korczynski’s enthusiasm reflects the importance of this new product launch. She stated, “I am honored to take on this role at such a pivotal time for Aquestive.” This sentiment captures the excitement surrounding Anaphylm's upcoming release and the significant market potential it holds.
Frequently Asked Questions
What is Sherry Korczynski’s new role at Aquestive Therapeutics?
Sherry Korczynski has been promoted to Chief Commercial Officer, guiding the global commercial strategy for Anaphylm.
What is Anaphylm?
Anaphylm is a sublingual film containing epinephrine, designed to be administered without water, making it convenient for those with anaphylaxis.
What previous experience does Korczynski bring to her new role?
Korczynski has over two decades of experience in commercial leadership, notably with EpiPen marketing during her tenure at Mylan.
How is Aquestive Therapeutics impacting patient care?
Aquestive Therapeutics is developing innovative drug delivery technologies to enhance patient outcomes and provide alternatives to standard treatments.
What educational background supports Korczynski’s leadership?
Korczynski holds a B.S. in Marketing from The Pennsylvania State University and an M.B.A. from West Virginia University.
